BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.90
+0.35 (4.64%)
At close: Feb 26, 2026, 4:00 PM EST
7.89
-0.01 (-0.13%)
Pre-market: Feb 27, 2026, 7:57 AM EST
BioCryst Pharmaceuticals Revenue
In the year 2025, BioCryst Pharmaceuticals had annual revenue of $874.84M with 94.10% growth.
Revenue (ttm)
$1.34B
Revenue Growth
+74.46%
P/S Ratio
2.24
Revenue / Employee
$1,508,340
Employees
580
Market Cap
1.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 874.84M | 424.13M | 94.10% |
| Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
| Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
| Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
| Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
| Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
| Dec 31, 2019 | 48.84M | 28.18M | 136.45% |
| Dec 31, 2018 | 20.65M | -4.53M | -18.00% |
| Dec 31, 2017 | 25.19M | -1.17M | -4.43% |
| Dec 31, 2016 | 26.35M | -21.90M | -45.39% |
| Dec 31, 2015 | 48.26M | 34.65M | 254.62% |
| Dec 31, 2014 | 13.61M | -3.72M | -21.48% |
| Dec 31, 2013 | 17.33M | -8.96M | -34.09% |
| Dec 31, 2012 | 26.29M | 6.65M | 33.85% |
| Dec 31, 2011 | 19.64M | -42.74M | -68.51% |
| Dec 31, 2010 | 62.38M | -12.21M | -16.37% |
| Dec 31, 2009 | 74.59M | 18.03M | 31.87% |
| Dec 31, 2008 | 56.56M | -14.68M | -20.60% |
| Dec 31, 2007 | 71.24M | 65.03M | 1,046.79% |
| Dec 31, 2006 | 6.21M | 6.06M | 3,990.38% |
| Dec 31, 2005 | 151.87K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Perrigo Company | 4.25B |
| Phibro Animal Health | 1.46B |
| Evotec SE | 887.40M |
| ANI Pharmaceuticals | 826.88M |
| Collegium Pharmaceutical | 780.57M |
| Amphastar Pharmaceuticals | 723.31M |
| HUTCHMED (China) | 602.20M |
BCRX News
- 16 hours ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - BioCryst Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 10 days ago - BioCryst to Present at Upcoming Investor Conference - GlobeNewsWire
- 16 days ago - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - GlobeNewsWire
- 22 days ago - BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - GlobeNewsWire
- 22 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - GlobeNewsWire
- 6 weeks ago - BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha